Envestnet Asset Management Inc. increased its position in shares of The Chemours Company (NYSE:CC – Get Rating) by 135.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,375 shares of the specialty chemicals company’s stock after acquiring an additional 24,390 shares during the period. Envestnet Asset Management Inc.’s holdings in Chemours were worth $1,298,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently bought and sold shares of the company. Lindbrook Capital LLC raised its stake in shares of Chemours by 117.3% during the 4th quarter. Lindbrook Capital LLC now owns 969 shares of the specialty chemicals company’s stock worth $30,000 after purchasing an additional 523 shares in the last quarter. TCI Wealth Advisors Inc. boosted its holdings in Chemours by 19.7% in the third quarter. TCI Wealth Advisors Inc. now owns 2,179 shares of the specialty chemicals company’s stock worth $54,000 after purchasing an additional 358 shares in the last quarter. IFP Advisors Inc boosted its stake in shares of Chemours by 9.0% during the 3rd quarter. IFP Advisors Inc now owns 4,610 shares of the specialty chemicals company’s stock worth $60,000 after acquiring an additional 382 shares in the last quarter. Old North State Trust LLC acquired a new position in shares of Chemours during the 3rd quarter valued at about $94,000. Finally, Harbor Investment Advisory LLC raised its stake in shares of Chemours by 20.1% in the 4th quarter. Harbor Investment Advisory LLC now owns 3,299 shares of the specialty chemicals company’s stock valued at $101,000 after acquiring an additional 551 shares in the last quarter. Institutional investors and hedge funds own 71.89% of the company’s stock.
Chemours Price Performance
Shares of NYSE:CC opened at $29.00 on Wednesday. The firm has a market capitalization of $4.33 billion, a PE ratio of 9.35, a PEG ratio of 0.94 and a beta of 1.87. The company has a current ratio of 1.84, a quick ratio of 0.98 and a debt-to-equity ratio of 2.93. The Chemours Company has a 1-year low of $23.58 and a 1-year high of $44.95. The business’s 50 day moving average is $29.11 and its 200-day moving average is $31.48.
Chemours Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 15th. Investors of record on Monday, May 15th will be given a $0.25 dividend. This represents a $1.00 annualized dividend and a yield of 3.45%. The ex-dividend date of this dividend is Friday, May 12th. Chemours’s dividend payout ratio (DPR) is presently 32.26%.
Insider Buying and Selling
In other news, insider Alisha Bellezza sold 27,716 shares of the company’s stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $35.47, for a total value of $983,086.52. Following the sale, the insider now directly owns 43,931 shares in the company, valued at approximately $1,558,232.57. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 1.63% of the company’s stock.
Analyst Upgrades and Downgrades
CC has been the topic of several analyst reports. Royal Bank of Canada increased their price target on Chemours from $35.00 to $36.00 in a report on Monday, May 1st. Credit Suisse Group dropped their target price on shares of Chemours from $27.00 to $25.00 in a report on Friday, April 28th. The Goldman Sachs Group upped their price target on shares of Chemours from $34.00 to $38.00 and gave the company a “neutral” rating in a report on Tuesday, February 14th. UBS Group raised Chemours from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $31.00 to $43.00 in a research report on Tuesday, January 24th. Finally, Citigroup raised their target price on Chemours from $33.00 to $35.00 and gave the company a “neutral” rating in a report on Monday, February 13th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Chemours presently has an average rating of “Hold” and an average price target of $36.11.
The Chemours Co is a holding company, which engages in the provision of performance chemicals. The firm delivers solutions, which include a range of industrial and chemical products for markets including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, and general industrial.
- Get a free copy of the StockNews.com research report on Chemours (CC)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Chemours Company (NYSE:CC – Get Rating).
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.